Sepsis‑associated acute kidney injury (SA‑AKI) is described as a lethal complication of sepsis with limited therapeutic options. Historically regarded as a metabolic waste product, lactate has been reinterpreted by recent discoveries as an active signaling metabolite. The identification of protein lactylation—a covalent modification where lactate modifies lysine residues—has reframed lactate as an epigenetic regulator with direct relevance to SA‑AKI pathogenesis.
The reviewed article positions lactylation as a central metabolic‑epigenetic hub that links altered metabolism in sepsis to downstream transcriptional and cellular responses in the kidney. This conceptual change expands potential mechanistic pathways to explain how metabolic derangements in sepsis drive renal injury.
Lactylation is governed by a dynamic molecular apparatus characterized in the review as a writer‑reader‑eraser network. Writers catalyze the installation of lactyl marks on lysine residues, readers recognize and interpret these modifications to effect downstream gene regulatory outcomes, and erasers remove the marks to allow reversibility.
The review summarizes this framework as foundational for understanding how lactylation controls epigenetic states and cellular phenotypes during SA‑AKI. Specific molecular components, enzymology, and site‑specific details beyond the general network characterization were not reported in the abstract.
A principal pathogenic axis described is immune reprogramming mediated by lactylation. In SA‑AKI, lactylation is reported to alter immune responses, including modulation of macrophage polarization. Through epigenetic modification of chromatin or regulatory proteins, lactylation can shift macrophage functional states, thereby contributing to the inflammatory milieu that promotes renal injury.
The review highlights immune modulation as a key mechanism linking metabolic changes in sepsis to maladaptive kidney inflammation.
Lactylation also influences renal tubular cell biology. The review indicates that lactylation can disrupt tubular cell fate decisions and is associated with mitochondrial dysfunction in tubular cells. These changes can favor injury pathways and impair cellular energy handling and recovery processes, exacerbating SA‑AKI.
The abstract emphasizes the role of lactylation in orchestrating intracellular processes central to tubular cell survival and function during sepsis.
Beyond immune and tubular cell effects, lactylation is implicated in compromising microvascular integrity within the kidney. Microvascular failure is an established contributor to organ dysfunction in sepsis, and the review situates lactylation as a mechanism that can impair vascular stability and perfusion, thereby worsening SA‑AKI.
A notable theme is that lactylation exhibits cell‑type and spatiotemporal specificity, which helps explain apparently contradictory roles reported in different contexts. Depending on the cell lineage and timing after septic insult, lactylation may promote injurious pathways or contribute to repair. The review argues that this specificity must be considered when interpreting functional consequences and when designing biomarker or therapeutic strategies.
The authors propose translational avenues grounded in the lactylation paradigm. Specific lactylation marks—cited in the abstract is H3K18 lactylation—are suggested as potential diagnostic biomarkers for SA‑AKI, reflecting epigenetic states linked to disease processes. Therapeutically, the lactylation axis represents a novel target space for precision interventions intended to modulate maladaptive metabolic‑epigenetic signaling in sepsis.
While the abstract identifies these opportunities, it does not provide experimental validation, predictive performance metrics for biomarkers, or details of therapeutic agents; such data would be found in the full text or subsequent studies.
The review concludes that although lactylation provides a compelling framework to connect metabolism and epigenetics in SA‑AKI, substantial research challenges remain. Translating mechanistic insights into clinical diagnostics or therapies requires addressing unresolved questions about molecular specificity, timing, cell‑type effects, and safety of interventions targeting epigenetic marks.
The abstract calls for continued work to overcome these obstacles so that modulation of the lactylation axis can be evaluated as a clinically useful strategy to improve outcomes in SA‑AKI.
(Notes: this summary and interpretation are based solely on the abstract of the cited review. Detailed experimental findings, quantitative results, and methodological specifics were not reported in the abstract and therefore are not represented here.)